Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of ubamatamab alone or with cemiplimab in recurrent ovarian and related MUC16-positive cancers
MOH_2023-06-29_012319Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ubamatamab, cemiplimab and sarilumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Objective response rate by RECIST 1.1, Safety profile and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
ubamatamabcemiplimabsarilumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2023-06-29_012319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-29_012319.